Clinicopathological features and prognosis of endometrial serous carcinoma

Purpose of investigation: To discuss the clinicopathological features, differential diagnosis, and prognosis of endometrial serous carcinoma (ESC). Materials and Methods: The clinical information of 33 patients aged 44-73 years, admitted to Yantai Huhuangding Hospital for surgical treatment of ESC between January 2003 and December 2013, were retrospectively reviewed. Immunohistochemistry analysis of estrogen (ER), progesterone (PR), and mutant type p53 (MTP53) markers were performed and their correlation with the clinical features and prognosis of ESC were studied. Results: Among all cases, 81.82% were ER− / PR− and 72.73% were MTP53+. Expression of ER, PR, and MTP53 markers were not affected by age, tumor size, infiltration depth, tumor staging or metastasis. P53mutation might be closely related to the tumorigenesis of ESC and lymphatic metastasis was a predictive factor for poor prognosis. Conclusion: This study provided us a better understanding of this rare type of carcinoma and could benefit future works of gynecologists, oncologists, and pathologists.

Endometrial cancer; Serous carcinoma; Mutant type p53; MTP53; Prognosis.

[1] SGO Clinical Practice Endometrial Cancer Working Group, Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., et al.: “Endometrial cancer: a review and current management strategies: part I”. Gynecol. Oncol. 2014, 134, 385.

[2] Porter S.: “Endometrial cancer”. Semin. Oncol. Nurs. 2002; 18:200.

[3] Berchuck A., Boyd J. “Molecular basis of endometrial cancer”. Cancer , 1995, 76, 2034.

[4] Wang Y., Xue F., Broaddus R.R., Tao X., Xie S.S., Zhu Y.: “Clinicopathological features in endometrial carcinoma associated with Lynch syndrome in China”. Int. J. Gynecol. Cancer, 2009, 19, 651.

[5] Setiawan V.W., Yang H.P., Pike M.C., McCann S.E., Yu H., Xiang Y.B., et al.: “Type I and II endometrial cancers: have they different risk factors?”. J. Clin. Oncol., 2013, 31, 2607.

[6] Park J.Y., Nam J.H., Kim Y.T., Kim Y.M., Kim J.H., Kim D.Y., et al.: “Poor prognosis of uterine serous carcinoma compared with grade 3 endometrioid carcinoma in early stage patients”. Virchows. Arch., 2013, 462, 289.

[7] Oncology F.C.o.G: “Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia”. Int. J. Gynaecol. Obstet., 2009, 105, 3.

[8] Kiernan J.A.: Histological and Histochemical Methods: Theory and Practice. 4th ed. Bloxham, UK: Scion, 2008.

[9] Sun D.Z., Xu L., Wei P.K., Liu L., He J.: “Syndrome differentiation in traditional Chinese medicine and E-cadherin/ICAM-1 gene protein expression in gastric carcinoma”. World J. Gastroenterol., 2007, 13, 4321.

[10] Daniilidou K., Frangou-Plemenou M., Grammatikakis J., Grigoriou O., Vitoratos N., Kondi-Pafiti A.: “Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study”. J. BUON., 2013, 18, 195.

[11] Semaan A., Mert I., Munkarah A.R., Bandyopadhyay S., Mahdi H.S., Winer I.S., et al.: “Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study”. Int. J. Gynecol. Pathol., 2013, 32, 181.

[12] Garg G., Gao F., Wright J.D., Hagemann A.R., Zighelboim I., Mutch D.G., Powell M.A.: “The risk of lymph node metastasis with positive peritoneal cytology in endometrial cancer”. Int. J. Gynecol. Cancer , 2013, 23, 90.

[13] Owings R.A., Quick C.M.: “Endometrial intraepithelial neoplasia”. Arch. Pathol. Lab. Med., 2014, 138, 484.

[14] Semere L.G., Ko E., Johnson N.R., Vitonis A.F., Phang L.J., Cramer D.W., Mutter G.L.: “Endometrial intraepithelial neoplasia: clinical correlates and outcomes”. Obstet. Gynecol.,2011, 118, 21.

[15] Darvishian F., Hummer A.J., Thaler H.T., Bhargava R., Linkov I., Asher M., Soslow R.A.: “Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases”. Am. J. Surg. Pathol., 2004, 28, 1568.

[16] Mhawech-Fauceglia P., Yan L., Liu S., Pejovic T.: “ER+ /PR+ /TFF3+ /IMP3- immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: a study of 401 cases”. Histopathology, 2013, 62, 976.

[17] Silva E.G., Deavers M.T., Parlow A.F., Gershenson D.M., Malpica A.: “Calcifications in ovary and endometrium and their neoplasms”. Mod. Pathol., 2003, 16, 219.

[18] Singh P., Scurry J., Proietto A.: “Lethal endometrial recurrence after cone biopsy for microinvasive cervical adenocarcinoma”. J. Obstet. Gynaecol. Res., 2008, 34, 413.

[19] Hu W.W., Tao J.H., Li G.M., Xu X., Yang X.M.: “Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas”. J. Southern. Med. Univ., 2010, 30, 526.

[20] Vang R., Whitaker B.P., Farhood A.I., Silva E.G., Ro J.Y., Deavers M.T.: “Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract”. Int. J. Gynecol. Pathol., 2001, 20, 252.

[21] Arai T., Watanabe J., Kawaguchi M., Kamata Y., Nishimura Y., Jobo T., Kuramoto H.: “Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma”. Int. J. Gynecol. Cancer, 2006, 16, 391.

[22] Marino-Enriquez A., Gonzalez-Rocha T., Burgos E., Stolnicu S., Mendiola M., Nogales F.F., Hardisson D.: “Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: a clinicopathologic study of 5 cases and review of the literature”. Hum. Pathol., 2008, 39, 1606.

[23] Zhang A.M., Zhang L.X., Zhang H.J. “Transitional cell carcinoma of the endometrium: a clinicopathological study of 3 cases”. Chin. J. Clin. Exp. Pathol., 2007, 23, 524.

[24] Zhu J., Sun H.: “Respective analysis of 54 cases uterine serous carcinoma”. Fudan Univ. J. Med. Sci., 2008, 35, 914.

[25] Kovalev S., Marchenko N.D., Gugliotta B.G., Chalas E., Chumas J., Moll U.M.: “Loss of p53 function in uterine papillary serous carcinoma”. Hum. Pathol. 1998, 29, 613.

[26] King S.A., Adas A.A., LiVolsi V.A., Takahashi H., Behbakht K., Mc-Govern P., et al.: “Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma”. Cancer, 1995, 75, 2700.

[27] Zheng W., Cao P., Zheng M., Kramer E.E., Godwin T.A. “p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes”. Gynecol. Oncol., 1996, 61, 167.

[28] Li M.Z., Wang Z.Q., Zhao L.J., Li X.P., Wang J.L., Zhang C.F., Wei L.H.: “Predictors of recurrence and prognosis in patients with stage I and II endometrial carcinoma”. Chin. J. Obstet. Gynecol., 2014, 49, 455.

[29] Mhawech-Fauceglia P., Herrmann R.F., Kesterson J., Izevbaye I., Lele S., Odunsi K.: “Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium”. Eur. J. Surg. Oncol., 2010, 36, 1195.